|Mr. Pascal Soriot D.V.M., M.B.A.||CEO & Exec. Director||5.92M||N/A||1959|
|Dr. Aradhana Sarin M.D.||Exec. Director||3.39M||N/A||1975|
|Ms. Pam P. Cheng||EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board||N/A||N/A||1971|
|Mr. Andrew P. Barnett||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Jeffrey Pott||CHRO, Chief Compliance Officer, Gen. Counsel & Member of External Sustainability Advisory Board||N/A||N/A||N/A|
|Gonzalo Vina||Head of Global Media Relations||N/A||N/A||N/A|
|Dr. Menelas Pangalos Ph.D.||EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board||N/A||N/A||1967|
|Dr. Ruud Dobber Ph.D.||Exec. Vice-Pres of BioPharmaceuticals Bus. Unit||N/A||N/A||N/A|
|Dr. Susan Mary Galbraith M.D., Ph.D.||Exec. VP of Oncology R&D||N/A||N/A||1966|
|Mr. Leon Wang||Exec. VP of International & China Pres||N/A||N/A||N/A|
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC’s ISS governance QualityScore as of 1 September 2023 is 2. The pillar scores are Audit: 7; Board: 2; Shareholder rights: 1; Compensation: 3.